WO2007142546A3 - Sustained release coated tablet with precisely regulated release profile - Google Patents

Sustained release coated tablet with precisely regulated release profile Download PDF

Info

Publication number
WO2007142546A3
WO2007142546A3 PCT/PL2007/000036 PL2007000036W WO2007142546A3 WO 2007142546 A3 WO2007142546 A3 WO 2007142546A3 PL 2007000036 W PL2007000036 W PL 2007000036W WO 2007142546 A3 WO2007142546 A3 WO 2007142546A3
Authority
WO
WIPO (PCT)
Prior art keywords
coated tablet
precisely regulated
sustained release
tablet
release profile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2007/000036
Other languages
French (fr)
Other versions
WO2007142546A2 (en
Inventor
Jaroslaw Mazgalski
Malcolm Stewart Frank Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zaklady Farmaceutyczne Polpharma SA
Original Assignee
Zaklady Farmaceutyczne Polpharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma SA filed Critical Zaklady Farmaceutyczne Polpharma SA
Priority to EP07747745A priority Critical patent/EP2023904A2/en
Publication of WO2007142546A2 publication Critical patent/WO2007142546A2/en
Publication of WO2007142546A3 publication Critical patent/WO2007142546A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a novel stable pharmaceutical composition in the form of a sustained release coated tablet comprising an active ingredient, carbomer and pharmaceutically acceptable excipients with a release profile that is precisely regulated by the parameters of the coating process, the use of carbomer for manufacturing the tablet and the process of coating the tablet using a water-based coating suspension.
PCT/PL2007/000036 2006-06-02 2007-06-01 Sustained release coated tablet with precisely regulated release profile Ceased WO2007142546A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07747745A EP2023904A2 (en) 2006-06-02 2007-06-01 Sustained release coated tablet with precisely regulated release profile

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL379831A PL204780B1 (en) 2006-06-02 2006-06-02 Coated tablet containing carbomer for extended release of indapamid, which release profile is adjusted exactly during the coating process
PLP-379831 2006-06-02

Publications (2)

Publication Number Publication Date
WO2007142546A2 WO2007142546A2 (en) 2007-12-13
WO2007142546A3 true WO2007142546A3 (en) 2008-02-21

Family

ID=38786936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2007/000036 Ceased WO2007142546A2 (en) 2006-06-02 2007-06-01 Sustained release coated tablet with precisely regulated release profile

Country Status (3)

Country Link
EP (1) EP2023904A2 (en)
PL (1) PL204780B1 (en)
WO (1) WO2007142546A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380561A1 (en) * 2010-04-21 2011-10-26 LEK Pharmaceuticals d.d. Extended release formulation comprising indapamide
WO2020109319A1 (en) 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061005A1 (en) * 1998-05-26 1999-12-02 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
WO2003057278A2 (en) * 2002-01-04 2003-07-17 Ivax Research, Inc. Drug delivery system for sustained delivery of glipizide
WO2004069234A1 (en) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
US20040208927A1 (en) * 2001-01-24 2004-10-21 Taro Pharmaceuticals U.S.A. Inc. Process for preparing non-hygroscopic sodium valproate composition
WO2005074884A2 (en) * 2004-01-30 2005-08-18 Krka, Tovarna Zdravil, D.D. Novo Mesto Sustained release pharmaceutical composition of indapamide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061005A1 (en) * 1998-05-26 1999-12-02 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US20040208927A1 (en) * 2001-01-24 2004-10-21 Taro Pharmaceuticals U.S.A. Inc. Process for preparing non-hygroscopic sodium valproate composition
WO2003057278A2 (en) * 2002-01-04 2003-07-17 Ivax Research, Inc. Drug delivery system for sustained delivery of glipizide
WO2004069234A1 (en) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
WO2005074884A2 (en) * 2004-01-30 2005-08-18 Krka, Tovarna Zdravil, D.D. Novo Mesto Sustained release pharmaceutical composition of indapamide

Also Published As

Publication number Publication date
EP2023904A2 (en) 2009-02-18
PL204780B1 (en) 2010-02-26
PL379831A1 (en) 2007-12-10
WO2007142546A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2010017821A8 (en) Coated tablets with a remaining degradation surface over the time
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2009090670A8 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
WO2011049309A3 (en) Pharmaceutical composition with both immediate and extended release characteristics
WO2008081891A1 (en) Orally disintegrating solid preparation
NZ589437A (en) Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
BRPI0910758A2 (en) thermostable solid composition, pharmaceutical composition, processes for preparing a thermostable solid composition and a pharmaceutical composition, method for improving the bioavailability of a pharmaceutically active ingredient, and
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2013009142A3 (en) Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
WO2007144169A3 (en) Entacapone-derivatives
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
HK1208620A1 (en) Pharmaceutical composition of entecavir and process of manufacturing
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2010026467A3 (en) Controlled release tablet of a highly water soluble active agent such as levetiracetam, or citicoline
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2007142546A3 (en) Sustained release coated tablet with precisely regulated release profile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07747745

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007747745

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU